![Scott Biller](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Scott Biller
Directeur/Membre du Conseil chez
FOGHORN THERAPEUTICS INC.
Fortune : - $ au 30/06/2026
Profil
Scott Biller is currently Director at OMass Therapeutics Ltd. since 2022, Independent Director at Foghorn Therapeutics, Inc. since 2020, Director at Remix Therapeutics, Inc. since 2020, and Director at Rome Therapeutics, Inc. since 2021.
Formerly, Dr. Biller was Chief Scientific Officer at Agios Pharmaceuticals, Inc. from 2010 to 2019, Vice President & Head-Global Discovery Chemistry at Novartis Institutes for Biomedical Research, Inc. from 2003 to 2010, and VP-Pharmaceutical Candidate Optimization at Bristol-Myers Squibb Pharmaceutical Research Institute from 2001 to 2003.
Education includes an undergraduate degree from Massachusetts Institute of Technology in 1976 and a doctorate from California Institute of Technology in 1981.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 24/06/2026 | 0 ( -.--% ) | - $ | 30/06/2026 |
Postes actifs de Scott Biller
| Sociétés | Poste | Début |
|---|---|---|
| FOGHORN THERAPEUTICS INC. | Directeur/Membre du Conseil | 09/01/2020 |
Remix Therapeutics, Inc.
 Remix Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company develops molecule therapies to modulate RNA processing and address the underlying drivers of diseases | Directeur/Membre du Conseil | 01/06/2020 |
Rome Therapeutics, Inc.
 Rome Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops novel therapies for cancer and autoimmune diseases | Directeur/Membre du Conseil | 01/02/2021 |
OMass Therapeutics Ltd.
 OMass Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Develops native mass spectrometry platform | Directeur/Membre du Conseil | 01/01/2022 |
Anciens postes connus de Scott Biller
| Sociétés | Poste | Fin |
|---|---|---|
| AGIOS PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 31/12/2019 |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Corporate Officer/Principal | 01/09/2010 |
Bristol-Myers Squibb Pharmaceutical Research Institute | Corporate Officer/Principal | 01/07/2003 |
Formation de Scott Biller
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
80
Relations au 1er degré
9
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
Agios Pharmaceuticals, Inc.
 Agios Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops therapeutics | Health Technology |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
California Institute of Technology
 California Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Commercial Services |
Bristol-Myers Squibb Pharmaceutical Research Institute | |
OMass Therapeutics Ltd.
OMass Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Develops native mass spectrometry platform | Commercial Services |
Foghorn Therapeutics, Inc.
 Foghorn Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops novel drugs to treat cancer and other serious medical disorders | Health Technology |
Rome Therapeutics, Inc.
Rome Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops novel therapies for cancer and autoimmune diseases | Health Technology |
Remix Therapeutics, Inc.
Remix Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company develops molecule therapies to modulate RNA processing and address the underlying drivers of diseases | Health Technology |
Choisissez Zonebourse 
